LucieFournier

Associate

Brussels + 32.2.645.15.47

Connect:

Share

Lucie Fournier works on European data protection and cybersecurity law, with a focus on implementing EU General Data Protection Regulation (GDPR) and ePrivacy Regulation (ePR) compliance. She advises multinational organizations in various industry sectors such as information and communications technology, cloud computing, IT, life sciences, automotive, online education, financial services, and agribusiness.

Lucie's practice includes advising clients on the implementation of global data protection compliance projects, international transfers of personal data (e.g., drafting data processing agreements with the new EU standard contractual clauses, developing data transfer impact assessments, drafting binding corporate rules, etc.), COVID-related data protection issues, the use of cookies, data subject access requests, personal data breaches, data protection impact assessments, and whistleblowing schemes.

Lucie also advises clients on data protection and cybersecurity issues in cross-border M&A transactions and investigations.

Prior to joining Jones Day, Lucie completed legal traineeships in the intellectual property and IT department of a U.S. law firm in Paris and at the French Ministry of Defense in Paris. She also has in-house experience as a legal adviser at a UK multinational company that focuses on defense, aerospace, and cybersecurity.

Experience

  • Consortium BelGaN Group BV acquires ON Semiconductor Belgium BVJones Day advised the consortium BelGaN Group BV with the acquisition of ON Semiconductor Belgium BV, a subsidiary of Semiconductor Components Industries, LLC, which designs and manufactures semiconductors components.
  • PTTGC acquires allnex from AdventJones Day advised PTT Global Chemical Public Company Limited in the €4 billion acquisition of allnex Holding GmbH from Advent International.
  • JBS acquires ViveraJones Day advised Brazilian JBS S.A., the world's largest protein company and second-largest food producer, in its acquisition of Vivera, Europe’s third-largest manufacturer of plant-based food, for an enterprise value of €341 million.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Bombardier sells transportation business to Alstom for €6.2 billionJones Day served as antitrust and French corporate counsel in the €6.2 billion sale of Bombardier Inc.'s transportation business to Alstom S.A.
  • International chemicals producer conducts internal auditJones Day is advising an international chemicals producer in conducting a multi-national internal antitrust audit.
  • Milliken & Company acquires Borchers from The Jordan CompanyJones Day advised Milliken & Company in its acquisition of Borchers Group Limited, a global specialty chemicals company known for its innovative high-performance coating additives and specialty catalyst solutions, from The Jordan Company, L.P.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
    • View All

    April 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 83

    April 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 81

    March 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 80

    March 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 79

    March 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 78

    February 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 77

    March 2022 Newsletters

    Vital Signs: Digital Health Law Update | Winter 2022

    February 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 76

    February 2022 Newsletters

    COVID-19 Key EU Developments, Policy & Regulatory Update No. 75

    February 2021 Commentary

    Health Care Organizations and Cloud Service Providers Receive Guidance on Cloud Security Measures
    View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.